Related Experiment Video
Updated: Jul 16, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
M H St Clair1, J L Martin, G Tudor-Williams
1Division of Virology, Burroughs Wellcome Co., Research Triangle Park, NC 27709.
Abstract:
Serial human immunodeficiency virus type-1 (HIV-1) isolates were obtained from five individuals with acquired immunodeficiency syndrome (AIDS) who changed therapy to 2',3'-dideoxyinosine (ddI) after at least 12 months of treatment with 3'-azido-3'-deoxythymidine (zidovudine, AZT). The in vitro sensitivity to ddI decreased during the 12 months following ddI initiation, whereas AZT sensitivity increased. Analysis of the reverse transcriptase coding region revealed a mutation associated with reduced sensitivity to ddI. When this mutation was present in the same genome as a mutation known to confer AZT resistance, the isolates showed increased sensitivity to AZT. Analysis of HIV-1 variants confirmed that the ddI resistance mutation alone conferred ddI and 2',3'-dideoxycytidine resistance, and suppressed the effect of the AZT resistance mutation. The use of combination therapy for HIV-1 disease may prevent drug-resistant isolates from emerging.
Related Concept Videos
Retrovirus Life Cycles
Viral Mutations
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Size and Structure of Viral Genomes
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly

